← Back to Search

Anti-microtubule agent

Paclitaxel + Radiation Therapy for Breast Cancer

Phase 2

Waitlist Available

Research Sponsored by Case Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

Study Summary

This trial is studying how well concurrent administration of paclitaxel and radiation therapy works in treating patients with stage II or stage III breast cancer.

Eligible Conditions

Breast Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Determine the feasibility of concurrent paclitaxel and breast radiotherapy

chemotherapy dose achieved during concurrent Taxol and radiation therapy.

Secondary outcome measures

Cosmetic outcome based upon established descriptive parameters: excellent, good, fair, and poor.

Pulmonary function

Survival

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Case Comprehensive Cancer CenterLead Sponsor

452 Previous Clinical Trials

31,866 Total Patients Enrolled

54 Trials studying Breast Cancer

4,923 Patients Enrolled for Breast Cancer

Janice Lyons, MDStudy ChairUniversity Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

3 Previous Clinical Trials

97 Total Patients Enrolled

3 Trials studying Breast Cancer

97 Patients Enrolled for Breast Cancer

Media Library

Paclitaxel (Anti-microtubule agent) Clinical Trial Eligibility Overview. Trial Name: NCT00006256 — Phase 2

Breast Cancer Clinical Trial 2023: Paclitaxel Highlights & Side Effects. Trial Name: NCT00006256 — Phase 2

Paclitaxel (Anti-microtubule agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00006256 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are septuagenarians being incorporated into this experimental research?

"The eligibility for this clinical trial is between 18 and 120 years of age, as outlined in the inclusion criteria."

Answered by AI

How secure is this approach to medical care for those it affects?

"There is limited data that implies the safety of this treatment, resulting in a rating of 2. This evaluation follows from its Phase 2 status which suggests some evidence for its security but none pertaining to efficacy."

Answered by AI

Are there any venues conducting this experiment domestically?

"There are a total of 9 clinical trial sites that have openings for enrolment. These include UH-Westlake located in Westlake, UH-CantonMercy situated in Canton and UH-Chagrin Highlands placed near Orange Village among the several others available."

Answered by AI

Are there any eligibility requirements to join this experiment?

"Potential participants in this trial must meet the criteria of having been diagnosed with breast cancer and falling between 18 to 120 years old. A total of 44 people are being recruited for participation."

Answered by AI

Is this investigation still open for participants?

"According to the clinicaltrials.gov database, this particular research is no longer recruiting participants; originally posted on June 8th 2000 and last edited July 12th 2023. Despite its closure, there are 2,677 other studies actively seeking volunteers at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer

2000. "Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00006256.